**See Lowe *et al.* (doi:10.1093/brain/awy226) for a scientific commentary on this article.**

Introduction
============

Alzheimer's disease is a progressive neurodegenerative brain disorder that is characterized pathologically by accumulation of fibrillar amyloid-β protein, probably starting 10--20 years before cognitive symptom onset, and formation of tau-containing neurofibrillary tangles, which are both spatially and temporally closely associated with neuronal degeneration and cognitive symptoms. A striking but little understood feature of both pathological alterations is that they affect discrete neural systems in a fairly consistent regional pattern while other brain regions are widely spared or only affected in very late stages of the disease ([@awy189-B6]; [@awy189-B76]). Multimodal neuroimaging techniques now allow imaging diverse aspects of Alzheimer's disease pathology in the living human brain, and greatly facilitate the brain-wide regional quantification of the pathological alterations due to markedly increased sampling rates when compared to laborious histopathological examinations. Thus, studies using amyloid-sensitive PET ligands have revealed a highly reproducible brain-wide pattern of regionally varying severity of amyloid deposition that is most pronounced in specific neocortical association areas. This amyloid pattern clearly deviates from the typical pattern of Alzheimer's disease-related neurodegeneration as detected by structural MRI, which is most pronounced in allocortical regions primarily affected by neurofibrillary tangles ([@awy189-B33]; [@awy189-B86]; [@awy189-B43]; [@awy189-B24]).

Elucidating the underlying principles that govern these differential regional vulnerabilities to amyloid deposition and neurodegeneration is of critical research interest, as it may yield important clues toward understanding the mechanisms of formation and progression of Alzheimer's disease pathology. A promising line of research towards this goal aims at characterizing the Alzheimer's disease-typical vulnerability patterns in relation to specific functional or structural properties of the human brain as assessed in healthy control populations ([@awy189-B7]; [@awy189-B69]; [@awy189-B79]; [@awy189-B63]; [@awy189-B89]; [@awy189-B32]; [@awy189-B72]; [@awy189-B15]; [@awy189-B58]; [@awy189-B56]). These studies collectively suggest that the regional vulnerability to Alzheimer's disease pathology may at least partly be determined by specific systemic limitations associated with the anatomo-functional properties of the affected neural systems ([@awy189-B35]; [@awy189-B34]). However, the precise properties that convey this elevated vulnerability remain poorly defined, and the strikingly different patterns of amyloid deposition and neurodegeneration strongly suggest that both aspects of Alzheimer's disease pathology are governed by diverging mechanisms.

Here we aimed to characterize the properties underlying regionally selective vulnerability to Alzheimer's disease-typical amyloid deposition and neurodegeneration further, by studying the neuroimaging patterns of these alterations in relation to the transcriptional architecture of the human brain as revealed by brain-wide regional gene expression profiling ([@awy189-B28], [@awy189-B27]). Regionally varying gene expression profiles reflect the molecular properties underlying inter-regional differences in anatomical ([@awy189-B20]; [@awy189-B84]; [@awy189-B71]) and functional ([@awy189-B23]; [@awy189-B27]; [@awy189-B64]; [@awy189-B81]; [@awy189-B41]) brain tissue characteristics, and may thus be ideally suited to study the shared features of Alzheimer's disease-vulnerable neural systems on a molecular level. While most previous studies examining relations between functional/structural characteristics of the human brain and regional vulnerability to Alzheimer's disease pathology have exclusively focused on either amyloid ([@awy189-B7]; [@awy189-B79]; [@awy189-B32]; [@awy189-B72]; [@awy189-B58]) or neurodegeneration ([@awy189-B69]; [@awy189-B63]; [@awy189-B89]; [@awy189-B15]), we conjointly estimated the respective patterns using multimodal amyloid-PET and structural MRI acquisitions, and studied the molecular properties underlying regional vulnerability to each type of pathological marker.

Based on previous neuropathological evidence for a regional correlation between amyloid deposition in Alzheimer's disease and amyloid precursor protein (APP) levels in neurologically normal brains ([@awy189-B72]), we first examined whether this spatial association may be reproduced using our combined neuroimaging-gene expression approach, and whether an analogous association may be observed between the MRI-based neurodegeneration pattern and expression levels of the microtubule-associated protein tau (*MAPT*) gene. Going beyond hypothesis-driven analyses of select candidate genes, we used explorative gene set enrichment analysis (GSEA) of the full genome-wide expression profiles ([@awy189-B75]) to characterize the molecular properties and related biochemical pathways underlying the distinct regional vulnerability patterns in a more comprehensive manner.

Material and methods
====================

Neuroimaging datasets
---------------------

The primary characterization of Alzheimer's disease-typical patterns of amyloid deposition and neurodegeneration used in this study was based on our previous analysis of combined ^18^F-florbetapir-PET and high-resolution structural MRI data of well-characterized samples of patients with Alzheimer's disease dementia (*n =*75) and healthy elderly controls (*n =*126) enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study ([@awy189-B24]).

Although the overall imaging patterns of Alzheimer's disease-typical amyloid deposition and neurodegeneration are very well described in the Alzheimer's disease neuroimaging literature ([@awy189-B33]; [@awy189-B86]; [@awy189-B43]; [@awy189-B24]), differences in patient characteristics, imaging acquisitions (e.g. choice of amyloid radiotracer, specific MRI sequence), and routines used for image processing and analysis may lead to some local variations in the derived patterns. Thus, in a complementary sensitivity analysis we derived Alzheimer's disease-typical patterns of amyloid deposition and neurodegeneration using combined ^18^F-flutemetamol-PET and high-resolution structural MRI data from independent samples of patients with Alzheimer's disease dementia (*n =*33) and healthy controls (*n =*28) enrolled in the Swedish BioFINDER study. Only patients with Alzheimer's disease dementia with a typical late-onset amnestic clinical presentation were selected from the larger patient sample of the BioFINDER cohort, given that phenotypic variants of Alzheimer's disease are known to associate with atypical neurodegeneration patterns ([@awy189-B59]).

Detailed diagnostic procedures as well as inclusion and exclusion criteria for the diagnostic categories in the ADNI and BioFINDER cohorts have been reported previously ([@awy189-B24]; [@awy189-B26]) and are detailed in the [Supplementary material](#sup1){ref-type="supplementary-material"}. Only clinically diagnosed patients with Alzheimer's disease dementia with (PET or CSF) biomarker evidence of cerebral amyloidosis were included in the patient samples, and cognitively normal controls with biomarker evidence of cerebral amyloidosis were excluded from the control samples. Demographic and clinical characteristics of the ADNI and BioFINDER samples are summarized in [Table 1](#awy189-t1){ref-type="table"}. Written informed consent was obtained from all study participants according to the Declaration of Helsinki, and ethical approval for data collection and sharing was given by the institutional review boards of the participating institutions in the ADNI and BioFINDER studies. Table 1Characteristics of ADNI and BioFINDER samples**ADNIBioFINDERCNADCNAD***n*126752833Age, years72.7 ± 6.475.0 ± 8.575.0 ± 5.674.8 ± 5.3Sex (M/F)65/6140/3517/1122/11Education, years16.8 ± 2.515.6 ± 2.812.5 ± 3.512.7 ± 3.8% APOE4[^a^](#tblfn1){ref-type="table-fn"}22%79%24%73%CDR (0/0.5/1/2/3)126/0/0/0/00/32/42/1/028/0/0/0/00/10/18/4/1CDR-SOB--4.5 ± 1.5--5.8 ± 3.6MMSE (a.u.)29.1 ± 1.222.9 ± 2.129.0 ± 1.122.1 ± 5.1[^2][^3][^4]

Neuroimaging acquisition and preprocessing
------------------------------------------

Details on image acquisition and preprocessing are provided in the [Supplementary material](#sup1){ref-type="supplementary-material"}. Briefly, all structural MRI data were acquired at 3T using high-resolution 3D T~1~-weighted imaging sequences. Preprocessing of these data followed a standard voxel-based morphometry approach within SPM software (<http://www.fil.ion.ucl.ac.uk/spm/>). Amyloid-PET data were acquired using ^18^F-florbetapir (ADNI) or ^18^F-flutemetamol (BioFINDER) radiotracers and PET scans were spatially normalized using registration parameters from co-registered MRIs and converted to voxel-wise maps of standard uptake value ratios (SUVRs) by scaling to signal in study-specific reference regions. Brain-wide patterns of Alzheimer's disease-typical amyloid deposition and neurodegeneration were finally estimated using voxel-wise Z-scores of preprocessed maps of amyloid-PET SUVR and MRI-derived grey matter volume, respectively. These Z-score maps represent in each voxel the mean difference between patients with Alzheimer's disease dementia and healthy controls scaled by the standard deviation of the control group ([@awy189-B24]; [@awy189-B26]).

Gene expression dataset
-----------------------

Regional gene expression profiles were assessed using microarray-based measurements of regional gene expression levels in the adult human brain that have been made publicly available by the Allen Brain Institute (<http://human.brain-map.org/>; RRID: SCR_007416). This worldwide unique data source constitutes the most comprehensive assessment of the transcriptional architecture of the human brain to date, and includes ∼62 000 microarray probes collected from 3700 regional brain tissue samples in autopsy data of six adult individuals (24--57 years) who had no known history of neuropsychiatric or neurological conditions ([@awy189-B28], [@awy189-B27]). In the dataset each regional sample is associated with an anatomical label as well as with a coordinate representing its approximate location in standard stereotactic space (MNI space). In the present study we used a previous anatomic mapping and inter-donor averaging of the regional expression values within the widely used anatomical parcellation scheme of the Desikan-Killiany cortical atlas ([@awy189-B17]). The final dataset includes median cortical expression profiles for 20 737 protein-coding genes of the human genome expressed as log~2~ expression values in each of the 34 Desikan-Killiany regions. Given that analyses of the bi-hemispheric data from the first two brain donors of the Allen brain atlas could not identify any interhemispheric asymmetries in gene expression ([@awy189-B28]), brain tissue collection in the subsequent brain donors was limited to the left hemisphere only ([@awy189-B27]). Thus, we restricted all our analyses to the more robust estimates of cortical gene expression profiles from the left hemisphere ([@awy189-B65]; [@awy189-B66]; [@awy189-B71]).

Statistical analysis
--------------------

In a first hypothesis-driven analysis, we aimed to quantify the spatial correspondence between Alzheimer's disease-typical imaging signatures of amyloid deposition and neurodegeneration and regional expression levels of *APP* and *MAPT* genes. For this, the imaging patterns were first mapped from voxel-level to the cortical parcellation scheme of the Desikan-Killiany atlas ([@awy189-B17]), and spatial associations with the gene expression profiles were then assessed using Spearman correlations across the 34 left-hemispheric cortical regions ([@awy189-B41]). Given that regional gene expression values vary to some degree across the six individual brain donors contributing to the Allen brain atlas ([@awy189-B17]), we further assessed the robustness of these imaging-genetic associations against variations in the donor sample used for calculating the median gene expression profiles. Thus, we used a Jackknife resampling technique to calculate median gene expression profiles for *APP* and *MAPT* using systematically varying subsamples of the data that only included four of the six brain donors (15 possible donor combinations). Spatial correlations with the Alzheimer's disease-typical imaging patterns were then calculated for each of the median gene expression profiles and averaged using Fisher weighted means.

We next explored genome-wide regional gene expression profiles associated with the respective pathological imaging patterns using a data-driven approach in combination with GSEA ([@awy189-B75]). In contrast to the hypothesis-testing analyses of *APP* and *MAPT* candidate genes, the principal aim of this approach was to generate new hypotheses about genes and pathways involved in regional vulnerability to Alzheimer's disease pathology. For each imaging pattern, we calculated spatial (Spearman) correlations for all 20 737 protein-coding genes in the dataset, and ranked the genes according to their spatial correlation values. The top (positive correlation) and bottom parts (negative correlation) of this ranked list contain the genes of interest, expression values of which increase or decrease, respectively, in relation to the regional vulnerability to Alzheimer's disease pathology. GSEA is a statistical approach explicitly designed to extract meaningful and interpretable information from high-throughput microarray data. Rather than selecting arbitrary sets of differentially expressed genes from the top or bottom of a ranked list based on statistical significance or effect size thresholds, GSEA uses the whole information inherent in the list to statistically assess whether prespecified gene sets, as a group, are significantly over- or under-represented (enriched) at the extremes of the list. A non-random distribution of a gene set across the ranked list is quantified by the normalized enrichment score, which also accounts for the differing sizes of the examined functional gene sets. Statistical significance of this score is assessed using permutation tests, and *P*-values are corrected for the independent testing of multiple gene sets using the false discovery rate (FDR). The threshold for statistical significance is set to *P*~FDR~ \< 0.05. The gene sets are defined by the common implication of the included genes in particular biological states or processes and are retrieved from a curated database (the Molecular Signatures Database; <http://software.broadinstitute.org/gsea/msigdb/index.jsp>). In the present study, we explored 1533 gene sets, including 497 curated and peer-reviewed gene sets of functional pathways derived from the Reactome database (<http://reactome.org/>), and 1036 gene sets that group genes annotated by the same gene ontology (GO) term (<http://www.geneontology.org/>).

To account for partial redundancy of the analysed gene sets and to help identifying the principal biological pathways revealed by the GSEA approach, the identified gene sets were organized into a network structure using the Cytoscape plug-in 'Enrichment Map' ([@awy189-B51]). Here, each gene set is plotted as a node and edges represent gene overlap between sets, resulting in an automated network layout that groups related gene sets into network clusters representing a common underlying pathway.

Data availability
-----------------

ADNI data is openly shared and was downloaded online at <https://ida.loni.usc.edu>. Processed ADNI data as well as BioFINDER data used in this study are not publicly available for download, but may be retrieved from the corresponding author upon request. Allen human brain atlas regional gene expression profiles mapped to the Desikan-Killiany cortical atlas were downloaded online at: <https://figshare.com/articles/A_FreeSurfer_view_of_the_cortical_transcriptome_generated_from_the_Allen_Human_Brain_Atlas/1439749>, and the original donor-specific microarray measurements are openly available at: <http://human.brain-map.org/static/download>.

Results
=======

Multimodal neuroimaging patterns of amyloid deposition and neurodegeneration in Alzheimer's disease
---------------------------------------------------------------------------------------------------

[Figure 1](#awy189-F1){ref-type="fig"} illustrates the brain-wide patterns of amyloid deposition and neurodegeneration in Alzheimer's disease as estimated by contrasting amyloid-sensitive ^18^F-florbetapir-PET and high-resolution structural MRI data of patients with Alzheimer's disease dementia and healthy controls from the ADNI cohort ([Table 1](#awy189-t1){ref-type="table"}). Regions of highest amyloid load correspond to distinct heteromodal association areas of the frontal, parietal, and lateral temporal lobes, whereas primary sensory-motor areas and the medial temporal lobe show the lowest vulnerability to amyloid deposition. By contrast, neurodegeneration is most pronounced in the medial temporal lobe, extending into lateral temporoparietal areas as well as anterior and posterior parts of the cingulate cortex. Primary sensory-motor areas, but also large parts of the frontal lobe appear to be relatively preserved from neurodegeneration.

![**Alzheimer's disease-typical neuroimaging patterns of amyloid deposition and neurodegeneration.** Alzheimer's disease-typical patterns of amyloid deposition (*top*) and neurodegeneration (*bottom*) as assessed by ^18^F-florbetapir-PET and structural MRI, respectively. Colour code reflects effect size (average z-score) of increased amyloid signal and decreased grey matter volume in patients with Alzheimer's disease as compared to healthy controls (ADNI cohort). L/R = left/right hemisphere.](awy189f1){#awy189-F1}

Associations of pathological imaging patterns with regional expression levels of *APP* and *MAPT* genes
-------------------------------------------------------------------------------------------------------

In a first hypothesis-driven analysis we assessed spatial associations of the Alzheimer's disease-typical patterns of amyloid deposition and neurodegeneration with regional expression levels of *APP* and *MAPT*, respectively. As illustrated in [Fig. 2](#awy189-F2){ref-type="fig"}, regional expression levels of *APP* were positively correlated with the severity of regional amyloid deposition (r = 0.44, *P =*0.009), but not neurodegeneration (r = 0.01, *P =*0.96). For *MAPT* expression levels the opposite pattern was observed, such that the severity of regional neurodegeneration in Alzheimer's disease (r = 0.46, *P =*0.006), but not severity of amyloid deposition (r = 0.08, *P =*0.65), increased with increasing levels of regional *MAPT* expression. A sensitivity analysis across gene expression profiles estimated from varying subsamples of the data fully reproduced these pathology-specific associations with regional *APP* and *MAPT* expression (average correlations: *APP*--amyloid, r = 0.38, *P =*0.03; *APP*--neurodegeneration, r = 0.15, *P =*0.40; *MAPT*--neurodegeneration, r = 0.40, *P =*0.02; *MAPT*--amyloid, r = 0.08, *P =*0.65), indicating that these differential spatial associations are not primarily driven by the gene expression data of any particular brain donor(s).

![**Associations of Alzheimer's disease-typical patterns of amyloid deposition and neurodegeneration with regional expression levels of *APP* and *MAPT* genes.** Regional severities of amyloid deposition (*top*) and neurodegeneration (*bottom*) are plotted against regional expression levels of *APP* (*left*) and *MAPT* (*right*) genes across 34 left-hemispheric cortical regions. Linear trends are indicated by regression lines and r indicates Spearman correlation coefficient. Green (*top left* and *bottom right*) and red (*top right* and *bottom left*) colours indicate statistical significance or non-significance, respectively, at a threshold of *P* \< 0.05.](awy189f2){#awy189-F2}

Genome-wide expression profiles associated with vulnerability to amyloid deposition and neurodegeneration in Alzheimer's disease
--------------------------------------------------------------------------------------------------------------------------------

Following up on the analysis based on *APP* and *MAPT* candidate genes, we aimed to determine gene expression profiles associated with vulnerability to Alzheimer's disease-typical amyloid deposition and neurodegeneration in a more comprehensive manner using a data-driven approach.

For the amyloid deposition pattern, GSEA revealed 18 gene sets to be negatively enriched and one gene set to be positively enriched in amyloid-vulnerable brain regions ([Table 2](#awy189-t2){ref-type="table"}). Visualization of the enrichment network showed that all but one of the underexpressed gene sets belonged to two distinct clusters, each grouping gene sets with overlapping gene members indicating a common underlying pathway ([Fig. 3](#awy189-F3){ref-type="fig"}). The biggest cluster (A1) mainly contained gene sets implicated in different aspects of protein synthesis, but also gene sets related to response to viral infection and immunity (cross-presentation). The other cluster (A2) contained three overlapping gene sets representing pathways of mitochondrial respiration, including the citric acid cycle and oxidative phosphorylation. Table 2Differentially-expressed gene sets in amyloid-vulnerable brain regionsClusterGene set nameGene set numberSizeNESFDR *P*-valueRepl. NESRepl. FDR *P*-value**Negatively enriched**A13 UTR MEDIATED TRANSLATIONAL REGULATION (REACTOME)194−2.66\<0.001−2.52\<0.001A1PEPTIDE CHAIN ELONGATION (REACTOME)276−2.58\<0.001−2.64\<0.001A1NONSENSE MEDIATED DECAY ENHANCED BY THE EXON JUNCTION COMPLEX (REACTOME)394−2.52\<0.001−2.46\<0.001A1TRANSLATION (REACTOME)4134−2.48\<0.001−2.21\<0.001A1INFLUENZA VIRAL RNA TRANSCRIPTION AND REPLICATION (REACTOME)590−2.44\<0.001−2.43\<0.001A1STRUCTURAL CONSTITUENT OF RIBOSOME (GO)668−2.42\<0.001−2.43\<0.001A1SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE (REACTOME)798−2.40\<0.001−2.28\<0.001A1FORMATION OF THE TERNARY COMPLEX AND SUBSEQUENTLY THE 43S COMPLEX (REACTOME)844−2.31\<0.001−2.12\<0.001A1ACTIVATION OF THE MRNA UPON BINDING OF THE CAP BINDING COMPLEX AND EIFS AND SUBSEQUENT BINDING TO 43S (REACTOME)951−2.30\<0.001−2.11\<0.001A1METABOLISM OF MRNA (REACTOME)10199−2.29\<0.001−1.93\<0.001A1INFLUENZA LIFE CYCLE (REACTOME)11124−2.27\<0.001−2.24\<0.001A1METABOLISM OF RNA (REACTOME)13242−2.15\<0.001−1.84\<0.001A1ER PHAGOSOME PATHWAY (REACTOME)1459−2.120.002−1.670.001A1ANTIGEN PROCESSING CROSS PRESENTATION (REACTOME)1572−2.030.006−1.580.011A2RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY UNCOUPLING PROTEINS (REACTOME)1281−2.150.009−1.90\<0.001A2TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT (REACTOME)16116−2.020.007−1.81\<0.001A2RESPIRATORY ELECTRON TRANSPORT (REACTOME)1765−2.010.008−1.81\<0.001-SMOOTH MUSCLE CONTRACTION (REACTOME)1822−2.000.007−1.620.022**Positively enriched**-OLFACTORY SIGNALING PATHWAY (REACTOME)193072.250.0062.13\<0.001[^5]

![**Network structure of negatively enriched gene sets in amyloid-vulnerable brain regions.** Negatively enriched gene sets (blue circles) are plotted in a graph structure, where the overlap in gene members between different gene sets is indicated by the width of cyan lines. Gene sets are numbered according to their order in [Table 2](#awy189-t2){ref-type="table"} and circle diameters reflect the size of each gene set. The matrix plot below shows the cluster structure of the leading-edge genes of the enriched gene sets (hierarchical clustering with average linkage). Each column corresponds to a leading-edge gene as detailed in [Supplementary Table 1](#sup2){ref-type="supplementary-material"}. Rows 1--14 contain the leading-edge genes of gene sets in cluster A1, rows 15--17 those of gene sets in cluster A2.](awy189f3){#awy189-F3}

For the neurodegeneration pattern, GSEA revealed 11 gene sets to be positively enriched in neurodegeneration-vulnerable brain regions, but no significantly negatively enriched gene sets ([Table 3](#awy189-t3){ref-type="table"}). Again, visualization of the enrichment network structure showed that several of the overexpressed gene sets overlapped in their gene members, resulting in three different clusters that contained gene sets related to 'cellular differentiation and neurite formation' (N1, four gene sets), 'extracellular signal-regulated kinase (MAPK/ERK) pathways' (N2, three gene sets), and 'proteoglycan metabolism' (N3, two gene sets) ([Fig. 4](#awy189-F4){ref-type="fig"}). Table 3Differentially-expressed gene sets in neurodegeneration-vulnerable brain regionsClusterGene set nameGene set numberSizeNESFDR *P*-valueRepl. NESRepl. FDR *P*-value**Positively enriched**N1NEURITE_DEVELOPMENT (GO)2522.150.0041.87\<0.001N1AXONOGENESIS (GO)5422.090.0051.97\<0.001N1CELLULAR MORPHOGENESIS DURING DIFFERENTIATION (GO)7482.070.0051.97\<0.001N1NEURON_DEVELOPMENT (GO)11602.010.0091.660.01N2SIGNALLING TO RAS (REACTOME)3262.100.0071.760.01N2SIGNALLING TO ERKS (REACTOME)8352.040.0071.530.013N2SHC RELATED EVENTS (REACTOME)10162.020.0091.910.003N3CHONDROITIN SULFATE DERMATAN SULFATE METABOLISM (REACTOME)1452.160.0091.96\<0.001N3A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS (REACTOME)4242.090.0052.04\<0.001-OXIDOREDUCTASE ACTIVITY ACTING ON THE ALDEHYDE OR OXO GROUP OF DONORSNAD OR NADP AS ACCEPTOR (GO)6162.080.0051.870.003-RAP1 SIGNALLING (REACTOME)9152.030.0091.570.031[^6]

![**Network structure of positively enriched gene sets in neurodegeneration-vulnerable brain regions.** Positively enriched gene sets (red circles) are plotted in a graph structure, where the overlap in gene members between different gene sets is indicated by the width of cyan lines. Gene sets are numbered according to their order in [Table 3](#awy189-t3){ref-type="table"} and circle diameters reflect the size of each gene set. The matrix plot below shows the cluster structure of the leading-edge genes of the enriched gene sets (hierarchical clustering with average linkage). Each column corresponds to a leading-edge gene as detailed in [Supplementary Table 2](#sup3){ref-type="supplementary-material"}. Rows 1 and 2 contain the leading-edge genes of gene sets in cluster N3, rows 3--5 those of gene sets in cluster N2, and rows 6--10 those of gene sets in cluster N1.](awy189f4){#awy189-F4}

Core differentially expressed genes within the identified pathways
------------------------------------------------------------------

Because statistical inference in GSEA is based on functional gene sets as a whole, not all of the genes included in a significant gene set need to be differentially expressed. The principal genes that account for a gene set's enrichment signal are called the leading-edge subset, and a leading-edge analysis aims to find commonalities among the most relevant genes of the identified pathways by clustering the respective leading-edge subsets ([@awy189-B75]). Detailing on the structure of the enrichment networks, this analysis revealed that the enrichment signals of the clustered gene sets were driven by highly overlapping subsets of differentially expressed genes ([Figs 3](#awy189-F3){ref-type="fig"}, [4](#awy189-F4){ref-type="fig"} and [Supplementary Tables 1](#sup2){ref-type="supplementary-material"} and [2](#sup3){ref-type="supplementary-material"}).

Thus, for cluster A1 of the amyloid-specific gene sets (protein synthesis) these included primarily genes coding for ribosomal proteins (RPS, RPL), which were the main contributors to the enrichment signal in 12 of 14 gene sets of this cluster, including those related to viral infection ([Supplementary Table 1](#sup2){ref-type="supplementary-material"}). The two gene sets related to immunity/cross-presentation were linked to cluster A1 by overlap of several leading-edge genes coding for proteins belonging to the proteasome (PSM) family. Enrichment signal of gene sets in cluster A2 (mitochondrial respiration) was driven by genes coding for several key enzymes of the citric acid cycle, as well as components of all complexes of the electron transport chain and ATP synthase.

On the other hand, overlapping leading-edge subsets of the neurodegeneration-specific cluster N1 (cellular differentiation/neurite formation) comprised genes coding for diverse classes of molecules jointly involved in developmental processes such as neurite outgrowth, axonal guidance, cytoskeletal flexibility, and synaptic contact ([Supplementary Table 2](#sup3){ref-type="supplementary-material"}). Some prominent examples include neurexin (*NRXN1*), neuropilin (*NRP2*), semaphorin (*SEMA4F*) and roundabout guidance (*ROBO1*, *ROBO2*) receptors, apolipoprotein E (*APOE*), microtubule-associated protein tau (*MAPT*), as well as cyclin dependent kinase 5 (*CDK5*) and its activator p35/25 (*CDK5R1*). Leading-edge genes of cluster N2 (MAPK/ERK signalling) comprised members from all steps of the MAPK/ERK signalling cascade, such as genes coding for adaptor/docking proteins (e.g. *GBR2*), Ras proteins (*HRAS*, *KRAS*, *NRAS*), and mitogen-activated protein kinases (e.g. *MAPK1*). Cluster N3 primarily included leading-edge genes coding for the glypican (GPC) and syndecan (SDC) families of heparan sulfate proteoglycans.

Sensitivity analysis using Alzheimer's disease-typical neuroimaging patterns derived from an independent cohort
---------------------------------------------------------------------------------------------------------------

To assess the robustness of our findings against study-related variations in the Alzheimer's disease-typical neuroimaging patterns, we examined whether the identified associations with gene expression profiles could be replicated when using regional vulnerability patterns derived from multimodal imaging data of an independent cohort of patients with Alzheimer's disease dementia and healthy controls (BioFINDER cohort, [Table 1](#awy189-t1){ref-type="table"}). Although some regional differences are evident when compared to the ADNI data, overall very similar brain-wide patterns of Alzheimer's disease-typical amyloid deposition and neurodegeneration were revealed in this cohort ([Fig. 5](#awy189-F5){ref-type="fig"}), resulting in high spatial correlations between the cohort-specific imaging patterns of r = 0.80 for amyloid deposition and r = 0.73 for neurodegeneration (both *P* \< 0.001). In accordance with our initial findings, the amyloid deposition pattern was spatially correlated with *APP* expression (r = 0.36, *P =*0.03), but not *MAPT* expression (r = 0.12, *P =*0.50). Similarly, the neurodegeneration pattern showed a higher spatial correlation with *MAPT* expression (r = 0.29, *P =*0.10) than with *APP* expression (r = 0.08, *P =*0.66), although the *MAPT*-neurodegeneration association only reached trend-level statistical significance here. Importantly, all of the differentially expressed gene sets identified by the GSEA approach in our primary analysis were also significantly enriched with respect to the vulnerability patterns defined by this independent cohort (including all of the *MAPT*-containing gene sets of cluster N1) ([Tables 2](#awy189-t2){ref-type="table"} and [3](#awy189-t3){ref-type="table"}).

![**Alzheimer's disease-typical neuroimaging patterns of amyloid deposition and neurodegeneration in replication cohort.** Alzheimer's disease-typical patterns of amyloid deposition (*top*) and neurodegeneration (*bottom*) as assessed by ^18^F-flutemetamol-PET and structural MRI, respectively, in the replication cohort (BioFINDER cohort; [Table 1](#awy189-t1){ref-type="table"}). Colour code reflects effect size (average z-score) of increased amyloid signal and decreased grey matter volume in patients with Alzheimer's disease as compared to healthy controls. L/R = left/right hemisphere.](awy189f5){#awy189-F5}

Discussion
==========

Understanding the regionally heterogeneous distribution of pathological alterations in Alzheimer's disease and the shared characteristics of those neural systems that are more vulnerable to Alzheimer's disease pathology than others is critical for a deeper understanding of Alzheimer's disease pathogenesis. By studying brain-wide patterns of Alzheimer's disease-typical neuroimaging abnormalities in relation to the transcriptional architecture of the human brain, this study shows that regional vulnerability to Alzheimer's disease pathology is linked to distinct molecular characteristics of the affected brain regions. Moreover, the deviating regional vulnerabilities to amyloid deposition and neurodegeneration were found to be associated with largely differing molecular profiles corresponding to distinct biochemical pathways of cellular functioning.

Regional correlations of Alzheimer's disease-typical amyloid and neurodegeneration patterns with expression levels of *APP* and *MAPT*
--------------------------------------------------------------------------------------------------------------------------------------

Our initial hypothesis-driven analysis showed that regional expression levels of *APP* in the human brain are predictive of the regional severity of amyloid deposition in Alzheimer's disease as measured by amyloid-sensitive PET. This indicates that a high regional content of amyloid precursor protein, which probably relates to specific characteristics of synaptic functioning in the local neuronal tissue ([@awy189-B10]; [@awy189-B29]; [@awy189-B40]), may increase a brain region's vulnerability to the accumulation of amyloid pathology in later life. Such a scenario would be supported by findings in trisomy 21, where the presence of an additional copy of the *APP* gene leads to an increased age-related amyloid accumulation in individuals with Down syndrome ([@awy189-B45]; [@awy189-B13]). A regional correlation between immunohistologically-determined APP levels in neurologically normal controls and accumulation of amyloid pathology in Alzheimer's disease had been shown previously based on neuropathological assessments across 12 different brain regions ([@awy189-B72]). While the neuroimaging approach used in the present study only provides an indirect surrogate marker for the extent of amyloid pathology, it enables considerably bigger sample sizes and higher regional sampling rates for a robust and spatially comprehensive estimation of the brain-wide pattern of amyloid deposition.

In addition to the regional correlation between *APP* expression and amyloid deposition, our analyses also demonstrated an analogous spatial association between *MAPT* expression levels and severity of neurodegeneration in Alzheimer's disease. The Alzheimer's disease-typical neurodegeneration pattern as measured by structural MRI closely resembles long-standing neuropathological estimates of the regional distribution of neurofibrillary tangle pathology in Alzheimer's disease ([@awy189-B6]; [@awy189-B86], [@awy189-B85]). Most recent findings from tau-sensitive PET imaging data largely confirm the spatial correspondence between accumulation of tau pathology and MRI-measured neurodegeneration in Alzheimer's disease ([@awy189-B9]; [@awy189-B88]), and further highlight marked differences between the typical allocortical-predominant pattern of tau/neurodegeneration and the neocortical-predominant pattern of amyloid deposition ([@awy189-B8]; [@awy189-B70]). Our finding of a regional correlation between *MAPT* expression levels and Alzheimer's disease-typical neurodegeneration agrees with findings from a recent study that examined differences in gene expression data from the Allen brain atlas between brain regions with high versus low vulnerability to tau pathology as defined by the Braak staging scheme ([@awy189-B16]). The study demonstrated differential expression of a set of candidate genes coding for proteins known to be involved in pathological protein aggregation in Alzheimer's disease, which on an individual gene level also included high *MAPT* expression levels in tau-vulnerable regions. These data collectively suggest that neural systems with a physiologically high content of tau may also be more vulnerable to pathological alterations of tau processing and subsequent neurofibrillary degeneration as the brain ages. Similarly, increased *MAPT* expression caused by a recently detected rare microduplication of the *MAPT* locus was found to lead to prominent neurofibrillary tangle pathology and an Alzheimer's disease dementia phenotype in the absence of notable amyloid pathology ([@awy189-B46]). However, although the previous study by [@awy189-B16] focused exclusively on tau-vulnerable regions, the analysed set of candidate genes did not distinguish between proteins involved in tau or amyloid aggregation, and thus it remains unknown whether the differential expression of this group of genes was primarily driven by tau-related proteins. An important methodological difference to our current study is the way in which vulnerable brain regions are defined and used to analyse the gene expression data. [@awy189-B16] manually selected dichotomous sets of tau-vulnerable and tau-resistant regions from the Allen brain atlas based on correspondence to previous descriptions of tau vulnerability in the literature \[i.e. the Braak staging scheme ([@awy189-B6])\]. By contrast, in the current study we used MRI data of well-characterized samples of patients with Alzheimer's disease and healthy controls to estimate a graded regional pattern of brain-wide vulnerability to Alzheimer's disease-typical neurodegeneration. This procedure allowed us to exploit the exceptionally dense regional gene expression information provided by the Allen brain atlas ([@awy189-B28]) in a spatial correlation approach.

Together, the distinct spatial associations of Alzheimer's disease-typical amyloid deposition and neurodegeneration with *APP* and *MAPT* expression levels support the hypothesis that the differential regional vulnerabilities to these pathological hallmarks are at least partly determined by regional differences in the neurotypical expression levels of the precursor proteins underlying the respective proteinopathic alteration. Using GSEA to more fully characterize the genome-wide expression profiles associated with vulnerability to amyloid deposition and neurodegeneration revealed that these different aspects of Alzheimer's disease pathology are generally related to markedly distinct biochemical pathways.

Biochemical pathways underlying vulnerability to amyloid deposition
-------------------------------------------------------------------

Amyloid-vulnerable brain regions were characterized by relatively low expression levels of gene sets implicated in protein synthesis and mitochondrial respiration. Besides genes of the ribosomal complex itself, the negatively enriched gene sets related to protein synthesis also included several underexpressed genes implicated in protein folding, degradation, and quality control mechanisms, including genes coding for proteasome proteins (PSM family), endoplasmatic chaperones (e.g. *HSPA1B*, *CALR* and *PDIA3*), and those implicated in non-sense mediated mRNA decay (e.g. *CASC3*). Neural systems with physiologically low expression levels of these genes might be more vulnerable to age-related dysfunctions in translation, protein folding and quality control mechanisms. While there is ample evidence implicating disturbed post-translational control mechanisms in amyloid aggregation and Alzheimer's disease ([@awy189-B55]; [@awy189-B48]), relatively less data are available for the role of ribosomal protein synthesis. Although it has long been known that Alzheimer's disease brain tissue is characterized by a severely decreased ribosomal protein synthesis, this has usually been interpreted as a consequence of pathology accumulation rather than its cause ([@awy189-B67]; [@awy189-B44]). However, a more recent study indicated that ribosome dysfunction may be among the earliest neurochemical alterations in Alzheimer's disease, although its relation to amyloid accumulation was not assessed directly ([@awy189-B12]). Potential mechanisms that could link ribosome dysfunction to amyloid accumulation include translational errors, such as ribosomal frameshifting ([@awy189-B78]; [@awy189-B87]), or a decreased ribosomal protein folding capability ([@awy189-B61]).

The finding that amyloid-vulnerable brain regions are characterized by comparably low expression levels of mitochondrial respiration genes is particularly intriguing as it coincides with a previous report of unexpectedly low rates of oxidative phosphorylation (when compared to overall glucose metabolism) in these brain regions; a phenomenon referred to as 'aerobic glycolysis' ([@awy189-B79]). Based on observations of activity-dependent increases in synaptic amyloid levels in animal models ([@awy189-B10]), regional vulnerability to amyloid deposition has been linked to high functional loads of the affected brain regions ([@awy189-B4]; [@awy189-B35]; [@awy189-B60]). Accordingly, in humans it could be demonstrated that the severity of amyloid deposition is spatially associated with the regional distribution of diverse markers of heightened neuronal activity in neurologically normal controls, including rates of ^18^F-fluorodeoxyglucose (FDG)-PET measured glucose metabolism ([@awy189-B58]), activation and connectivity patterns in functional MRI data ([@awy189-B7]; [@awy189-B73]), as well as immunohistological levels of synaptic marker proteins ([@awy189-B72]). However, notwithstanding these overall brain-wide associations, comparably high neuronal activity is also characteristic for some brain regions that are largely spared from amyloid deposition (e.g. the primary visual cortex), indicating that vulnerability to amyloid deposition may relate to some specific characteristic of neuronal/synaptic activity, rather than high activity levels *per se* ([@awy189-B58]; [@awy189-B60]). The highly interconnected heteromodal association areas that are primarily affected by amyloid deposition are characterized by a range of neuronal properties that allow them to support large-scale synchronous activity, such as optimized biophysical properties for maintaining spike bursts ([@awy189-B7]; [@awy189-B60]). This functional characteristic might put these brain regions at increased need for rapid energy generation through the use of aerobic glycolysis ([@awy189-B79]; [@awy189-B35]), thus possibly providing the link to the low expression of mitochondrial respiration genes observed here. Notably, experimental manipulation of mitochondrial function in animal models could provide initial evidence for a causal influence of decreased mitochondrial energy production on increased amyloid deposition through disrupted clearance mechanisms ([@awy189-B68]; [@awy189-B42]). Although a previous study in humans could link genetic variants within oxidative phosphorylation genes to an increased Alzheimer's disease risk, no effects on CSF markers of amyloid pathology were observed in this study ([@awy189-B5]). The relation between mitochondrial energy metabolism and amyloid pathology in the natural human disease course remains to be elucidated in more detail.

Interestingly, *APP* was not included among the genes identified in the genome-wide enrichment analysis. This may indicate that APP only plays a secondary role for determining regional amyloid load in sporadic Alzheimer's disease when compared to other pathways, consistent with previous findings ([@awy189-B72]). While an alternative explanation would be that APP and its processing pathways are not well represented in the analysed gene set databases, additional analyses on *APP*-related gene sets argue against such an analytic confound ([Supplementary material](#sup1){ref-type="supplementary-material"}).

Biochemical pathways underlying vulnerability to Alzheimer's disease-typical neurodegeneration
----------------------------------------------------------------------------------------------

In contrast to the low expression levels of specific gene sets in amyloid-vulnerable areas, brain regions vulnerable to Alzheimer's disease-typical neurodegeneration were characterized by comparably high expression levels of genes implicated in biological functions ranging from neurite outgrowth and synaptic contact over intracellular signalling cascades to proteoglycan metabolism. Interestingly, at the individual gene level this data-driven analysis corroborated the association with *MAPT* expression, and additionally identified some of the best described tau kinases (CDK5, MAPK1/ERK2) alongside components of their Ras-ERK activation pathways ([@awy189-B14]; [@awy189-B11]; [@awy189-B50]).

While at first sight the overexpressed gene sets appear to represent separate biochemical pathways, a common denominator of the related functions may be a high capacity for neuroplastic change. Thus, the physiological functions of tau protein and its associated kinases have been implicated in cytoskeletal flexibility, dendritic spine formation, and also more functional aspects of synaptic plasticity such as long-term depression ([@awy189-B39]; [@awy189-B54]; [@awy189-B83]; [@awy189-B31]). Tau function is physiologically regulated by its phosphorylation state, and even transient hyperphosphorylation of tau can be observed under specific physiological conditions, where it has been associated with adaptive neuroprotective changes of the synapse ([@awy189-B2]; [@awy189-B82]). Furthermore, both signalling in the MAPK/ERK pathway and proteoglycan metabolism have been implicated in diverse aspects of neural plasticity. Specifically, Ras-mediated activation of downstream MAPK/ERK kinases has been shown to regulate plastic mechanisms of synaptic function ([@awy189-B74]), whereas heparan sulfate proteoglycans play relevant roles in activity-dependent synaptic reorganization and neurogenesis ([@awy189-B49]; [@awy189-B47]; [@awy189-B53]). Similarly, the overexpression of APOE within the molecular profile related to neurodegeneration vulnerability might be explained by its physiological function in synaptic plasticity ([@awy189-B38]), although allelic variants of this Alzheimer's disease risk gene have been more closely linked to amyloid deposition than to tau/neurodegeneration ([@awy189-B37]; [@awy189-B22]; [@awy189-B25]) (see [Supplementary material](#sup1){ref-type="supplementary-material"} for an extended discussion of this rather unexpected spatial association).

This *post hoc* interpretation of the neurodegeneration-related molecular profile to be reflective of a high plastic potential would be consistent with previous reports highlighting the disproportionately high capacity for plastic change in tau-vulnerable brain regions ([@awy189-B1]; [@awy189-B80]). This coincidence is particularly striking in the medial temporal allocortex, which attracts by far the highest amount of neurofibrillary pathology ([@awy189-B6]) and at the same time is one of the most plastic neural systems in the human brain, characterized by high rates of experience-dependent synaptic reorganization and the selective capability of adult neurogenesis ([@awy189-B3]; [@awy189-B21]). Based on diverse lines of evidence it has been hypothesized that a high potential for lifelong adaptive reorganization, while instrumental for supporting memory formation and other higher cognitive functions, may become a risk factor for maladaptive processes resulting in pathological tau hyperphosphorylation and associated neurodegeneration as the brain ages ([@awy189-B57]; [@awy189-B52]; [@awy189-B1]). In this context it is notable that a dual role in neural plasticity and neurofibrillary degeneration not only characterizes tau and its phosphorylation pathways ([@awy189-B82]; [@awy189-B83]), but also applies to heparan sulfate proteoglycans, which in addition to their role in neural plasticity ([@awy189-B49]; [@awy189-B53]) have long been identified as key factors in the formation of neurofibrillary tangle pathology in Alzheimer's disease ([@awy189-B19]; [@awy189-B77]; [@awy189-B30]). Thus, in neuropathological studies heparan sulfate proteoglycans were found to co-localize with hyperphosphorylated tau at the earliest stages of neurofibrillary tangle pathology, and *in vitro* experiments revealed that they can prevent tau from binding to microtubules and induce its aggregation into paired helical filaments ([@awy189-B19]). More recent work could further show that heparan sulfate proteoglycans promote transcellular tau propagation by binding extracellular tau fibrils on the cell surface ([@awy189-B30]). Together, the distinct molecular profile associated with vulnerability to Alzheimer's disease-typical neurodegeneration identified in the present study is largely consistent with the notion of a selective vulnerability caused by a high potential for plastic change.

Limitations
-----------

In this study we used a cortical parcellation scheme of 34 anatomically defined brain regions that is widely used in the neuroimaging literature (Desikan-Killiany cortical atlas; [@awy189-B17]). However, when compared to the spatially detailed parcellations revealed by recent multi-modal mappings of human brain organization ([@awy189-B18]), this anatomical parcellation likely involves averaging gene expression data across structurally and functionally heterogeneous brain areas. Although the used gene expression data from the Allen brain atlas provide the anatomically most comprehensive transcriptome data for the human brain available to date ([@awy189-B36]), the spatial coverage would probably not be sufficient to accurately estimate gene expression profiles at much higher spatial resolutions. Even for the relatively coarse anatomical parcellation into 34 cortical regions, some of the regions only contain a limited number of tissue samples stemming from a subset of available brain donors ([@awy189-B17]). Thus, at higher regional granularities the decreasing number of tissue samples per region would markedly increase the influence of noise from single microarray measurements and interindividual variance on the estimated gene expression profiles. Similarly, the limited availability of right hemispheric gene expression measurements in the Allen brain atlas has prevented us from studying potential effects of brain asymmetries on the imaging-genetic spatial associations. However, interhemispheric symmetry is evident in the Alzheimer's disease-typical imaging patterns ([Figs 1](#awy189-F1){ref-type="fig"} and [5](#awy189-F5){ref-type="fig"}) and can also be reasonably assumed for the gene expression profiles ([@awy189-B28]; [@awy189-B62]).

Finally, we note that our explorative GSEA approach explicitly focused on the identification of pathways that were most robustly associated with each imaging pattern separately, and may thus not be sensitive for the detection of interacting pathways associated with both amyloid and neurodegeneration. A more focused investigation of interacting gene networks that may potentially link both types of Alzheimer's disease pathology is a promising avenue for future research.

Conclusion
==========

This study shows that the regional vulnerability to Alzheimer's disease pathology relates to specific molecular properties of the affected neural systems, and that the biochemical pathways underlying this vulnerability largely differ for amyloid accumulation versus neurodegeneration. While these molecular properties may equip the respective neural systems with specific functional characteristics necessary for efficient information processing in the context of higher cognitive functions, they may come with the downside of an elevated vulnerability to maladaptive cellular processes and pathological alterations during brain ageing. The identification of distinct molecular properties underlying regional vulnerability to amyloid deposition and neurodegeneration provides novel insights into the complex pathophysiological mechanisms of Alzheimer's disease and points to pathology-specific treatment targets that warrant further exploration in independent studies.
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ADNI

:   Alzheimer's Disease Neuroimaging Initiative

GSEA

:   gene set enrichment analysis

MAPK/ERK

:   mitogen-activated protein kinases/extracellular signal-regulated kinases

[^1]: Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu/>). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>

[^2]: Average values are reported as mean ± SD.

[^3]: AD = Alzheimer's disease dementia patients; CDR-SOB = Clinical Dementia Rating -- Sum of Boxes; CN*=*cognitively normal controls; F = female; M = male; MMSE = Mini-Mental State Examination; *n =*sample size.

[^4]: ^a^Persons with at least one APOE4 allele; *APOE* genotype was not available for eight ADNI participants (three cognitively normal and five with Alzheimer's disease).

[^5]: NES = normalized enrichment score; Repl. = Replication values using neuroimaging patterns derived from the BioFINDER cohort.

[^6]: NES = normalized enrichment score; Repl. = Replication values using neuroimaging patterns derived from the BioFINDER cohort.
